Trellegy Ellipta Hits Phase 3 Asthma Marks, Eyes New Indication
May 5th 2019Pivotal phase 3 trial results show benefits for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Trelegy Ellipta) in patients with uncontrolled asthma compared with standard FF/VI (Breo Ellipta) therapy.
Read More
Beta Interferon Treatment Shown to Improve Long-Term Survival in Patients with MS
May 4th 2019In the first and largest study of its kind, researchers from the University of British Columbia (UBC) and Vancouver Coastal Health Research Institute aimed to assess mortality associated with beta interferons for the treatment of MS.
Read More
Adjuvant Treatment for HER2+ Early Breast Cancer Receives FDA Approval
May 4th 2019The FDA rapidly reviewed and approved Genentech’s application under the FDA’s Real-Time Oncology Review (RTOR) and Assessment Aid pilot programs, leading to an approval 12 weeks after completing the submission.
Read More
New Data Support Viral Suppression as Key to Preventing HIV Transmission
May 3rd 2019Results of the recent study, published in The Lancet, support the benefits of early testing and treatment for HIV, as well as the message of Prevention Access Campaign’s U=U (undetectable equals untransmittable) initiative.
Read More
Ivosidenib as Monotherapy Granted FDA Approval for Certain Patients with IDH1 Mutant AML
May 3rd 2019The sNDA was granted Priority Review and accepted under the agency's Real-Time Oncology Review pilot program, which aims to make the review of oncology drugs more efficient by allowing the FDA access to clinical trial data before the information is formally submitted to the agency.
Read More
Ivosidenib as Monotherapy Granted FDA Approval for Certain Patients with IDH1 Mutant AML
May 3rd 2019The sNDA was granted Priority Review and accepted under the agency's Real-Time Oncology Review pilot program, which aims to make the review of oncology drugs more efficient by allowing the FDA access to clinical trial data before the information is formally submitted to the agency.
Read More
First Vaccine for Dengue Disease Prevention Receives FDA Approval
May 2nd 2019The drug application was granted the FDA’s Priority Review designation, as well as a Tropical Disease Priority Review Voucher under a program intended to encourage development of new drugs and biologics for the prevention and treatment of certain tropical diseases.
Read More
Walgreen's, UC College of Pharmacy Partner for Specialty Pharmacy Education
May 1st 2019Partnerships like the UC College of Pharmacy and Walgreens offer opportunities for experience with complex disease states, such as cancer, multiple sclerosis, HIV, and Crohn’s disease, that many students will see after they graduate.
Read More
Bipolar Disorder: Opportunity for Pharmacists to Improve Adherence and Health Outcomes
As highly accessible health care professionals, pharmacists have the opportunity to improve medication adherence and health outcomes of patients with bipolar disorder.
Read More